{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CDC25", "CHK1", "PTEN", "RB1", "TP53", "WEE1", "basal-like breast cancer", "checkpoint control", "therapy", "triple negative breast cancer"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "29617654", "DateCompleted": {"Year": "2019", "Month": "09", "Day": "03"}, "DateRevised": {"Year": "2022", "Month": "08", "Day": "08"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1016/j.celrep.2018.03.039", "S2211-1247(18)30381-4"], "Journal": {"ISSN": "2211-1247", "JournalIssue": {"Volume": "23", "Issue": "1", "PubDate": {"Year": "2018", "Month": "Apr", "Day": "03"}}, "Title": "Cell reports", "ISOAbbreviation": "Cell Rep"}, "ArticleTitle": "Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.", "Pagination": {"StartPage": "112", "EndPage": "126", "MedlinePgn": "112-126"}, "Abstract": {"AbstractText": ["CDK4/6 inhibitors are effective against cancer cells expressing the tumor suppressor RB1, but not RB1-deficient cells, posing the challenge of how to\u00a0target RB1 loss. In triple-negative breast cancer (TNBC), RB1 and PTEN are frequently inactivated\u00a0together with TP53. We performed kinome/phosphatase\u00a0inhibitor screens on primary mouse Rb/p53-, Pten/p53-, and human RB1/PTEN/TP53-deficient TNBC cell lines and identified CDC25 phosphatase as a common target. Pharmacological or genetic inhibition of CDC25 suppressed growth of RB1-deficient TNBC cells that are resistant to combined CDK4/6 plus CDK2 inhibition. Minimal cooperation was observed in\u00a0vitro between CDC25 antagonists and CDK1, CDK2, or CDK4/6 inhibitors, but strong synergy with WEE1 inhibition was apparent. In accordance with increased PI3K signaling following long-term CDC25 inhibition, CDC25 and PI3K inhibitors effectively synergized to suppress TNBC growth both in\u00a0vitro and in xenotransplantation models. These results provide a rationale for the development of CDC25-based therapies for diverse RB1/PTEN/TP53-deficient and -proficient TNBCs."], "CopyrightInformation": "Copyright \u00a9 2018 The Author(s). Published by Elsevier Inc. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 67 College Street, Toronto, ON, Canada M5G 2M1."}], "LastName": "Liu", "ForeName": "Jeff C", "Initials": "JC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 67 College Street, Toronto, ON, Canada M5G 2M1; Department of Agriculture, Food, and Environmental Sciences, University of Perugia, Perugia, Italy."}], "LastName": "Granieri", "ForeName": "Letizia", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 67 College Street, Toronto, ON, Canada M5G 2M1; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada."}], "LastName": "Shrestha", "ForeName": "Mariusz", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 67 College Street, Toronto, ON, Canada M5G 2M1."}], "LastName": "Wang", "ForeName": "Dong-Yu", "Initials": "DY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 67 College Street, Toronto, ON, Canada M5G 2M1; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada."}], "LastName": "Vorobieva", "ForeName": "Ioulia", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Lunenfeld-Tanenbaum Research Institute, Sinai Health System, 600 University Avenue, Toronto, ON, Canada."}], "LastName": "Rubie", "ForeName": "Elizabeth A", "Initials": "EA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 67 College Street, Toronto, ON, Canada M5G 2M1."}], "LastName": "Jones", "ForeName": "Rob", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 67 College Street, Toronto, ON, Canada M5G 2M1."}], "LastName": "Ju", "ForeName": "YoungJun", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Donnelly Centre, University of Toronto, Toronto, ON, Canada; The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON, Canada."}], "LastName": "Pellecchia", "ForeName": "Giovanna", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 67 College Street, Toronto, ON, Canada M5G 2M1."}], "LastName": "Jiang", "ForeName": "Zhe", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Agriculture, Food, and Environmental Sciences, University of Perugia, Perugia, Italy."}], "LastName": "Palmerini", "ForeName": "Carlo A", "Initials": "CA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academic of Sciences, Guiyang, Guizhou 550014, China; State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, Guizhou 550025, China."}], "LastName": "Ben-David", "ForeName": "Yaacov", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada; Program in Cell Biology, The Peter Gilgan Center for Research and Learning, The Hospital for Sick Children, Toronto, ON, Canada."}], "LastName": "Egan", "ForeName": "Sean E", "Initials": "SE"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Lunenfeld-Tanenbaum Research Institute, Sinai Health System, 600 University Avenue, Toronto, ON, Canada."}], "LastName": "Woodgett", "ForeName": "James R", "Initials": "JR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Donnelly Centre, University of Toronto, Toronto, ON, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada."}], "LastName": "Bader", "ForeName": "Gary D", "Initials": "GD"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Agriculture, Food, and Environmental Sciences, University of Perugia, Perugia, Italy; Network Biology Collaborative Centre, SMART Laboratory for High-Throughput Screening Programs, Mount Sinai Hospital, Toronto, ON, Canada."}], "LastName": "Datti", "ForeName": "Alessandro", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 67 College Street, Toronto, ON, Canada M5G 2M1; Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address: eldad.zacksenhaus@utoronto.ca."}], "LastName": "Zacksenhaus", "ForeName": "Eldad", "Initials": "E"}], "GrantList": [{"GrantID": "P41 GM103504", "Acronym": "GM", "Agency": "NIGMS NIH HHS", "Country": "United States"}, {"GrantID": "R01 GM070743", "Acronym": "GM", "Agency": "NIGMS NIH HHS", "Country": "United States"}, {"GrantID": "U41 HG006623", "Acronym": "HG", "Agency": "NHGRI NIH HHS", "Country": "United States"}, {"Agency": "CIHR", "Country": "Canada"}], "PublicationTypeList": ["Journal Article", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Cell Rep", "NlmUniqueID": "101573691"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Enzyme Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Retinoblastoma Binding Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Suppressor Protein p53"}, {"RegistryNumber": "EC 3.1.3.48", "NameOfSubstance": "cdc25 Phosphatases"}, {"RegistryNumber": "EC 3.1.3.67", "NameOfSubstance": "PTEN Phosphohydrolase"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Enzyme Inhibitors"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred NOD"}, {"QualifierName": [], "DescriptorName": "Mice, SCID"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "PTEN Phosphohydrolase"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Retinoblastoma Binding Proteins"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Triple Negative Breast Neoplasms"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Tumor Suppressor Protein p53"}, {"QualifierName": ["antagonists & inhibitors", "genetics", "metabolism"], "DescriptorName": "cdc25 Phosphatases"}], "CoiStatement": "DECLARATION OF INTERESTS. The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Bartek J, and Lukas J (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421\u2013429.", "ArticleIdList": ["12781359"]}, {"Citation": "Boutros R, Lobjois V, and Ducommun B (2007). CDC25 phosphatases in cancer cells: key players? Good targets? Nat. Rev. Cancer 7, 495\u2013507.", "ArticleIdList": ["17568790"]}, {"Citation": "Brezak MC, Quaranta M, Mond\u00e9sert O, Galcera MO, Lavergne O, Alby F, Cazales M, Baldin V, Thurieau C, Harnett J, et al. (2004). A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res 64, 3320\u20133325.", "ArticleIdList": ["15126376"]}, {"Citation": "Brezak MC, Valette A, Quaranta M, Contour-Galcera MO, Jullien D, Lavergne O, Frongia C, Bigg D, Kasprzyk PG, Prevost GP, and Ducommun B (2009). IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells. Int. J. Cancer 124, 1449\u20131456.", "ArticleIdList": ["19065668"]}, {"Citation": "Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, Hershko A, Pagano M, and Draetta GF (2003). Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426, 87\u201391.", "ArticleIdList": ["14603323"]}, {"Citation": "Caino MC, Ghosh JC, Chae YC, Vaira V, Rivadeneira DB, Faversani A, Rampini P, Kossenkov AV, Aird KM, Zhang R, et al. (2015). PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proc. Natl. Acad. Sci. USA 112, 8638\u20138643.", "ArticleIdList": ["PMC4507184", "26124089"]}, {"Citation": "Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G Jr., Ranashinge M, Cady B, Pagano M, and Loda M (2000). Role of the Cdc25A phosphatase in human breast cancer. J. Clin. Invest 106, 753\u2013761.", "ArticleIdList": ["PMC381390", "10995786"]}, {"Citation": "Cho YC, Park JE, Park BC, Kim JH, Jeong DG, Park SG, and Cho S (2015). Cell cycle-dependent Cdc25C phosphatase determines cell survival by regulating apoptosis signal-regulating kinase 1. Cell Death Differ 22, 1605\u20131617.", "ArticleIdList": ["PMC4563786", "25633196"]}, {"Citation": "Chou TC, and Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul 22, 27\u201355.", "ArticleIdList": ["6382953"]}, {"Citation": "Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al.; METABRIC Group (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352.", "ArticleIdList": ["PMC3440846", "22522925"]}, {"Citation": "Dalvai M, Mondesert O, Bourdon JC, Ducommun B, and Dozier C (2011). Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors. Oncogene 30, 2282\u20132288.", "ArticleIdList": ["21242964"]}, {"Citation": "Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe RT Jr., et al. (2002). Retraction. Science 298, 2327.", "ArticleIdList": ["12526115"]}, {"Citation": "Dominguez-Brauer C, Thu KL, Mason JM, Blaser H, Bray MR, and Mak TW (2015). Targeting mitosis in cancer: emerging strategies. Mol. Cell 60, 524\u2013536.", "ArticleIdList": ["26590712"]}, {"Citation": "Dvinge H, Git A, Gr\u00e4f S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, et al. (2013). The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497, 378\u2013382.", "ArticleIdList": ["23644459"]}, {"Citation": "Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al. (2009). PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11, R77.", "ArticleIdList": ["PMC2790859", "19874578"]}, {"Citation": "Galaktionov K, Chen X, and Beach D (1996). Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382, 511\u2013517.", "ArticleIdList": ["8700224"]}, {"Citation": "Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, et al. (2010). A pathway-based classification of human breast cancer. Proc. Natl. Acad. Sci. U S A 107, 6994\u20136999.", "ArticleIdList": ["PMC2872436", "20335537"]}, {"Citation": "Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, et al. (2017). CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471\u2013475.", "ArticleIdList": ["PMC5570667", "28813415"]}, {"Citation": "Guo J, Parise RA, Joseph E, Lan J, Pan SS, Joo B, Egorin MJ, Wipf P, Lazo JS, and Eiseman JL (2007). Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003\u20131 (NSC 663284). Anticancer Res 27 (5A), 3067\u20133073.", "ArticleIdList": ["17970046"]}, {"Citation": "Guo SL, Ye H, Teng Y, Wang YL, Yang G, Li XB, Zhang C, Yang X, Yang ZZ, and Yang X (2013). Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Nat. Commun 4, 2544.", "ArticleIdList": ["PMC3826643", "24149576"]}, {"Citation": "Hazzalin CA, Le Panse R, Cano E, and Mahadevan LC (1998). Anisomycin selectively desensitizes signalling components involved in stress kinase activation and fos and jun induction. Mol. Cell. Biol 18, 1844\u20131854.", "ArticleIdList": ["PMC121414", "9528756"]}, {"Citation": "He R, Zeng LF, He Y, Zhang S, and Zhang ZY (2013). Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J 280, 731\u2013750.", "ArticleIdList": ["PMC3495087", "22816879"]}, {"Citation": "Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, et al. (2016). Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 76, 2301\u20132313.", "ArticleIdList": ["PMC5426059", "27020857"]}, {"Citation": "Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, et al. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8, R76.", "ArticleIdList": ["PMC1929138", "17493263"]}, {"Citation": "Herschkowitz JI, He X, Fan C, and Perou CM (2008). The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 10, R75.", "ArticleIdList": ["PMC2614508", "18782450"]}, {"Citation": "Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, Weigman VJ, Tsao MS, Lane TF, Perou CM, and Zacksenhaus E (2010). Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J. Clin. Invest 120, 3296\u20133309.", "ArticleIdList": ["PMC2929714", "20679727"]}, {"Citation": "Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, and Zacksenhaus E (2011). RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 10, 1563\u20131570.", "ArticleIdList": ["21502814"]}, {"Citation": "Jones RA, Robinson TJ, Liu JC, Shrestha M, Voisin V, Ju Y, Chung PE, Pellecchia G, Fell VL, Bae S, et al. (2016). RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J. Clin. Invest 126, 3739\u20133757.", "ArticleIdList": ["PMC5096803", "27571409"]}, {"Citation": "Kitajima S, and Takahashi C (2017). Intersection of retinoblastoma tumor suppressor function, stem cells, metabolism, and inflammation. Cancer Sci 108, 1726\u20131731.", "ArticleIdList": ["PMC5581511", "28865172"]}, {"Citation": "Knudsen ES, and Witkiewicz AK (2017). The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies. Trends Cancer 3, 39\u201355.", "ArticleIdList": ["PMC5347397", "28303264"]}, {"Citation": "Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, et al.; Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370.", "ArticleIdList": ["PMC3465532", "23000897"]}, {"Citation": "Kristj\u00e1nsd\u00f3ttir K, and Rudolph J (2004). Cdc25 phosphatases and cancer. Chem. Biol 11, 1043\u20131051.", "ArticleIdList": ["15324805"]}, {"Citation": "Kuntz EM, Baquero P, Michie AM, Dunn K, Tardito S, Holyoake TL, Helgason GV, and Gottlieb E (2017). Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat. Med 23, 1234\u20131240.", "ArticleIdList": ["PMC5657469", "28920959"]}, {"Citation": "Lawrence RT, Perez EM, Hern\u00e1ndez D, Miller CP, Haas KM, Irie HY, Lee SI, Blau CA, and Vill\u00e9n J (2015). The proteomic landscape of triple-negative breast cancer. Cell Rep 11, 630\u2013644.", "ArticleIdList": ["PMC4425736", "25892236"]}, {"Citation": "Liu H, Nishitoh H, Ichijo H, and Kyriakis JM (2000). Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol. Cell. Biol 20, 2198\u20132208.", "ArticleIdList": ["PMC110836", "10688666"]}, {"Citation": "Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, and Yung WK (2009). NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther 8, 2204\u20132210.", "ArticleIdList": ["PMC2752877", "19671762"]}, {"Citation": "Liu JC, Voisin V, Wang S, Wang DY, Jones RA, Datti A, Uehling D, Al-awar R, Egan SE, Bader GD, et al. (2014). Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol. Med 6, 1542\u20131560.", "ArticleIdList": ["PMC4287974", "25330770"]}, {"Citation": "Liu H, Tang X, Srivastava A, P\u00e9cot T, Daniel P, Hemmelgarn B, Reyes S, Fackler N, Bajwa A, Kladney R, et al. (2015). Redeployment of Myc and E2f1\u20133 drives Rb-deficient cell cycles. Nat. Cell Biol 17, 1036\u20131048.", "ArticleIdList": ["PMC4526313", "26192440"]}, {"Citation": "Ma CX, Janetka JW, and Piwnica-Worms H (2011). Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol. Med. 17, 88\u201396.", "ArticleIdList": ["PMC6905465", "21087899"]}, {"Citation": "Medema RH, and Mac\u016frek L (2012). Checkpoint control and cancer. Oncogene 31, 2601\u20132613.", "ArticleIdList": ["21963855"]}, {"Citation": "Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, et al. (2016). Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354.", "ArticleIdList": ["PMC4910866", "27135926"]}, {"Citation": "Otto T, and Sicinski P (2017). Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17, 93\u2013115.", "ArticleIdList": ["PMC5345933", "28127048"]}, {"Citation": "Prat A, and Perou CM (2011). Deconstructing the molecular portraits of breast cancer. Mol. Oncol 5, 5\u201323.", "ArticleIdList": ["PMC5528267", "21147047"]}, {"Citation": "Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, and Perou CM (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12, R68.", "ArticleIdList": ["PMC3096954", "20813035"]}, {"Citation": "Robinson TJ, Liu JC, Vizeacoumar F, Sun T, Maclean N, Egan SE, Schimmer AD, Datti A, and Zacksenhaus E (2013). RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS ONE 8, e78641.", "ArticleIdList": ["PMC3827056", "24265703"]}, {"Citation": "Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, et al. (2017). Integrative clinical genomics of metastatic cancer. Nature 548, 297\u2013303.", "ArticleIdList": ["PMC5995337", "28783718"]}, {"Citation": "Santamar\u00eda D, Barri\u00e9re C, Cerqueira A, Hunt S, Tardy C, Newton K, C\u00e1ceres JF, Dubus P, Malumbres M, and Barbacid M (2007). Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448, 811\u2013815.", "ArticleIdList": ["17700700"]}, {"Citation": "Tibbles LA, and Woodgett JR (1999). The stress-activated protein kinase pathways. Cell. Mol. Life Sci 55, 1230\u20131254.", "ArticleIdList": ["PMC11147067", "10487205"]}, {"Citation": "Tyanova S, Albrechtsen R, Kronqvist P, Cox J, Mann M, and Geiger T (2016). Proteomic maps of breast cancer subtypes. Nat. Commun 7, 10259.", "ArticleIdList": ["PMC4725767", "26725330"]}, {"Citation": "Vigo E, M\u00fcller H, Prosperini E, Hateboer G, Cartwright P, Moroni MC, and Helin K (1999). CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol. Cell. Biol 19, 6379\u20136395.", "ArticleIdList": ["PMC84608", "10454584"]}, {"Citation": "Vir\u00e9 E, Curtis C, Davalos V, Git A, Robson S, Villanueva A, Vidal A, Barbieri I, Aparicio S, Esteller M, et al. (2014). The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. Mol. Cell 53, 806\u2013818.", "ArticleIdList": ["PMC3988886", "24582497"]}, {"Citation": "Wang S, Liu JC, Kim D, Datti A, and Zacksenhaus E (2016). Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer. Breast Cancer Res 18, 9.", "ArticleIdList": ["PMC4717616", "26781438"]}, {"Citation": "Wang S, Liu JC, Ju Y, Pellecchia G, Voisin V, Wang DY, Leha LR, Ben-David Y, Bader GD, and Zacksenhaus E (2017). microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer. JCI Insight 2, 93313.", "ArticleIdList": ["PMC5543917", "28768903"]}, {"Citation": "Witkiewicz AK, Chung S, Brough R, Vail P, Franco J, Lord CJ, and Knudsen ES (2018). Targeting the vulnerability of RB tumor suppressor loss in triple-negative breast cancer. Cell Rep 22, 1185\u20131199.", "ArticleIdList": ["PMC5967622", "29386107"]}, {"Citation": "Zacksenhaus E, Shrestha M, Liu JC, Vorobieva I, Chung PED, Ju Y, Nir U, and Jiang Z (2017). Mitochondrial OXPHOS induced by RB1 deficiency in breast cancer: implications for anabolic metabolism, stemness, and metastasis. Trends Cancer 3, 768\u2013779.", "ArticleIdList": ["29120753"]}, {"Citation": "Zou X, Tsutsui T, Ray D, Blomquist JF, Ichijo H, Ucker DS, and Kiyokawa H (2001). The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1. Mol. Cell. Biol 21, 4818\u20134828.", "ArticleIdList": ["PMC87174", "11416155"]}]}], "History": [{"Year": "2017", "Month": "10", "Day": "23"}, {"Year": "2018", "Month": "1", "Day": "31"}, {"Year": "2018", "Month": "3", "Day": "11"}, {"Year": "2018", "Month": "4", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "4", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "9", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "7"}], "PublicationStatus": "ppublish", "ArticleIdList": ["29617654", "NIHMS1826944", "PMC9357459", "10.1016/j.celrep.2018.03.039", "S2211-1247(18)30381-4"]}}]}